Menu Search
Equities

Quest Diagnostics Inc

QDI:STU

Quest Diagnostics Inc

Actions
Health CareMedical Equipment and Services
  • Price (EUR)151.45
  • Today's Change-0.80 / -0.53%
  • Shares traded0.00
  • 1 Year change+22.43%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Quest Diagnostics Inc's revenues fell -6.38% from 9.88bn to 9.25bn. This along with an increase in the cost of goods sold expense has contributed to a reduction in net income from 946.00m to 854.00m, a -9.73% decrease.
Gross margin32.94%
Net profit margin9.10%
Operating margin13.13%
Return on assets5.87%
Return on equity12.66%
Return on investment6.77%
More ▼

Cash flow in USDView more

In 2023, Quest Diagnostics Inc increased its cash reserves by 117.78%, or 371.00m. The company earned 1.27bn from its operations for a Cash Flow Margin of 13.75%. In addition the company generated 160.00m cash from financing while 1.06bn was spent on investing.
Cash flow per share11.87
Price/Cash flow per share13.52
Book value per share60.79
Tangible book value per share-31.36
More ▼

Balance sheet in USDView more

Quest Diagnostics Inc has a Debt to Total Capital ratio of 47.46%, a lower figure than the previous year's 61.42%.
Current ratio1.25
Quick ratio1.17
Total debt/total equity0.918
Total debt/total capital0.4746
More ▼

Growth rates in USD

SmartText is unavailable
Div yield(5 year avg)1.75%
Div growth rate (5 year)7.43%
Payout ratio (TTM)38.78%
EPS growth(5 years)7.78
EPS (TTM) vs
TTM 1 year ago		11.75
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.